At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia or Lymphoma, or Biphenotypic Leukemia
In Brief
A Phase 2 clinical trial evaluating Busulfan, Clofarabine, and 2 other interventions for Leukemia and 3 related conditions. Completed, enrolled 120 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to test the safety of giving clofarabine in combination with busulfan, followed by an allogeneic (from a donor) stem cell transplant, in patients with advanced leukemia or lymphoma.
Study Details
Timeline
Interventions
Test Dose 32 mg/m\^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
40 mg/m\^2 by vein over 1 hour daily Day -6 through Day -3
0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
Stem cell infusion on Day 0.